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In pathophysiological events such as ischemia 
and infl   ammation, host angiogenic responses 
are increased at the site of injury due, in part, to 
the release of growth factors such as vascular 
endothelial growth factor (VEGF) and chemo-
kines such as stromal cell–derived factor 1 
(SDF-1) (1). These factors function by increas-
ing vascular permeability, promoting endothe-
lial cell activation and migration, proliferation, 
and, eventually, capillary formation. Recent 
studies have suggested an important role for 
SDF-1 in the recruitment of endothelial pro-
genitor cells (EPCs) to home to sites of injury 
and facilitate repair (2–5). SDF-1 (also referred 
to as CXCL12) binds to a high affi   nity recep-
tor, CXC chemokine receptor 4 (CXCR4), 
and is the predominant chemokine that mobi-
lizes hematopoietic stem cells and EPCs (6–8).
Inactivation of SDF-1 and its receptor 
CXCR4 in mice causes embryonic lethality 
because of abnormal vascular formation in the 
brain and gastrointestinal tract and altered he-
matopoiesis (9–12). Overexpression of SDF-1 
in ischemic tissues enhances EPC recruitment 
from peripheral blood to induce neovasculari-
zation (5, 13). Ischemia increases SDF-1 lev-
els and leads to increased EPC numbers and 
  formation of new blood vessels in the injured 
tissue (14). In a model of hypoxia-induced retinal 
neovascularization, SDF-1 levels are elevated 
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Stromal cell–derived factor 1 (SDF-1) plays a major role in the migration, recruitment, and 
retention of endothelial progenitor cells to sites of ischemic injury and contributes to 
neovascularization. We provide direct evidence demonstrating an important role for heme 
oxygenase 1 (HO-1) in mediating the proangiogenic effects of SDF-1. Nanomolar concen-
trations of SDF-1 induced HO-1 in endothelial cells through a protein kinase C 𝗇–dependent 
and vascular endothelial growth factor–independent mechanism. SDF-1–induced 
endo  thelial tube formation and migration was impaired in HO-1–defi  cient cells. Aortic 
rings from HO-1−/− mice were unable to form capillary sprouts in response to SDF-1, a 
defect reversed by CO, a byproduct of the HO-1 reaction. Phosphorylation of vasodilator-
stimulated phosphoprotein was impaired in HO-1−/− cells, an event that was restored by 
CO. The functional signifi  cance of HO-1 in the proangiogenic effects of SDF-1 was con-
fi  rmed in Matrigel plug, wound healing, and retinal ischemia models in vivo. The absence of 
HO-1 was associated with impaired wound healing. Intravitreal adoptive transfer of HO-1–
defi  cient endothelial precursors showed defective homing and reendothelialization of the 
retinal vasculature compared with HO-1 wild-type cells following ischemia. These fi  ndings 
demonstrate a mechanistic role for HO-1 in SDF-1–mediated angiogenesis and provide new 
avenues for therapeutic approaches in vascular repair.
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in the vitreous humor, and administration of an anti–SDF-1 
antibody prevents recruitment of GFP-positive endothelial 
precursors in the eye (15). The exact mechanisms for the 
proangiogenic eff  ects of SDF-1 are not clearly understood.
Recent studies have suggested a role for heme oxygenase 1 
(HO-1) in angiogenesis (16–21). HO-1, a 32-kD stress-  inducible 
enzyme, catalyzes the rate-limiting step in the   degradation of 
heme, resulting in the liberation of iron, CO, and biliverdin 
(22). Biliverdin is then converted to bilirubin by biliverdin 
reductase. HO-1 is highly inducible after exposure to a wide 
variety of prooxidant stimuli, including heme, heavy metals, 
hydrogen peroxide, cytokines,   modifi  ed lipids, growth factors 
(e.g., TGF-β and platelet-derived growth factor), hypoxia and 
hyperoxia, glucose deprivation, and others (23). Induction of 
HO-1 occurs as an adaptive and benefi  cial response to tissue 
injury (24, 25), eff  ects that are mediated through one or more 
of the products, which have vasodilatory, antiinfl  ammatory, 
and antiapoptotic properties (24, 26, 27).
The studies supporting a role for HO-1 in angiogenesis 
have shown that proangiogenic factors such as VEGF activate 
HO-1 expression in endothelial cells in vitro (21, 28, 29). 
Furthermore, local HO inhibition with metalloporphyrins 
blocks angiogenesis and tumor growth in vivo (17, 30). 
However, the importance of HO-1 in SDF-1–mediated 
Figure 1.  SDF-1 induces HO-1 expression in HAECs. (A) Time course 
of HO-1 mRNA induction in HAECs exposed to SDF-1 at 100 ng/ml (equiv-
alent to 14 nM) at the indicated times. The blots were reprobed with HO-2 
and GAPDH as a loading control. (B) Northern blot showing induction 
of HO-1 mRNA after 4 h of treatment with the indicated concentrations 
of SDF-1. (C and D) Western blots showing HO-1 and actin protein levels 
in HAECs incubated with 100 ng/ml SDF-1 for the indicated times (C) and 
concentrations of SDF-1 for 8 h (D). (E) HO enzyme activity in HAECs 
treated with vehicle (PBS), 5 μM hemin, or 200 ng/ml SDF-1 for 6 and 16 h, 
respectively. Enzyme activity is expressed as pmol bilirubin/mg protein/h. 
Results are expressed as mean ± SEM. *, P < 0.001 versus vehicle-treated 
cells (n = 2–4 per group). (F) Specifi  city of HO-1 mRNA induction by 
100 ng/ml SDF-1 after incubation of HAECs with 50 μg/ml of an anti–SDF-1 
antibody (SDF-1 ab). (G) Western blots showing HO-1 and actin levels in 
HAECs treated with the indicated concentrations of the CXCR-4 antagonist 
AMD 3100 for 1 h, followed by stimulation with SDF-1 for 8 h. (H) Half-life 
and stability of SDF-1–induced HO-1 mRNA. HAECs were preincubated 
with SDF-1 for 4 h and exposed to 4 μM actinomycin D (Actino) in the 
absence or presence of additional SDF-1. Northern blot analysis was per-
formed as described in Supplemental materials and methods. (I) HAECs 
were treated with Actino or cycloheximide (Cyclo), and HO-1 mRNA induc-
tion by 100 ng/ml SDF-1 for 4 h was examined by Northern blot analysis.JEM VOL. 204, March 19, 2007  607
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angiogenesis is not known. Given the potential for the pro-
angiogenic eff  ects of HO-1, we sought to examine if the 
eff  ects of SDF-1 were mediated through the induction of 
HO-1 in endothelial cells and EPCs. In this study, we dem-
onstrate that SDF-1 activates HO-1 expression in human and 
mouse aortic endothelial cells (MAECs) and mouse EPCs. 
Pharmacological inhibition of HO activity or genetic abla-
tion of HO-1 resulted in the loss of SDF-1–mediated endo-
thelial tube formation in vitro and sprouting from aortic rings 
ex vivo, eff  ects that were restored by the addition of CO but 
not bilirubin. HO-1 was also required for the eff  ects of SDF-1 
on the migration of mature endothelial cells and circulating 
endothelial precursors in vitro, as well as in vivo in Matrigel 
plug, wound healing, and retinal ischemia models of angio-
genesis. We also demonstrate that SDF-1–mediated HO-1 
induction occurs by a protein kinase C (PKC) ζ–dependent 
and VEGF-independent mechanism. In addition, we have 
identifi  ed vasodilator-stimulated phosphoprotein (VASP), a 
cytoskeletal-associated protein involved in migration (31), as 
a downstream target for SDF-1 that requires HO-1–derived 
CO for phosphorylation.
RESULTS
SDF-1 induces HO-1 expression in human aortic endothelial 
cells (HAECs)
To examine whether SDF-1 modulates HO-1 expression, 
HAECs were treated with 100 ng/ml (equivalent to 14 nM) 
SDF-1 for 0, 2, 4, 6, 8, 16, and 24 h. Northern blot anal-
ysis revealed a time-dependent induction of HO-1 mRNA 
by SDF-1, with maximal expression at 4 h (Fig. 1 A; see 
Supplemental materials and methods, available at http://
www.jem.org/cgi/content/full/jem.20061609/DC1). HO-2 
mRNA levels were unchanged during this treatment (Fig. 
1 A). SDF-1–mediated HO-1 induction was also dose depen-
dent (Fig. 1 B). Treatment with 100 and 200 ng/ml SDF-1 
resulted in an approximately six- and eightfold induction of 
HO-1 mRNA, respectively. The increase in HO-1 mRNA 
in response to SDF-1 also resulted in an increase in HO-1 
protein levels in a time- and dose-dependent fashion (Fig. 
1, C and D), with a maximal response at 16 h. A time-
dependent increase in HO enzyme activity was also observed 
in HAECs after SDF-1 treatment (Fig. 1 E). A 2.5-fold 
  increase of HO activity at 6 h and a 5-fold increase at 16 h, 
respectively, were observed in HAECs after treatment with 
200 ng/ml SDF-1. The increase in activity observed was 
comparable to that observed with 5 μM hemin, a known 
inducer of HO-1.
Because the eff  ects of SDF-1 are mediated via CXCR4, 
we analyzed HAECs by fl   ow cytometry for the popula-
tion of cells expressing CXCR4 receptor and observed that 
38.7% of HAECs expressed CXCR4 (unpublished data). We 
then investigated the specifi  city of SDF-1–mediated HO-1 
  induction using an anti–SDF-1 antibody. As shown in Fig. 
1 F, neutralization of SDF-1 with 50 μg/ml of the anti-
body reduced HO-1 mRNA induction, demonstrating the 
specifi  city of SDF-1. Additionally, treatment with increasing 
concentrations (3–300 nM) of a CXCR-4 antagonist, AMD 
3100, dose-dependently inhibited the SDF-1–mediated HO-1 
induction (Fig. 1 G). Collectively, these results demonstrate 
that nanomolar concentrations of SDF-1 induce HO-1 
mRNA, protein, and enzyme activity in HAECs through the 
CXCR-4 receptor.
Pretreatment of HAECs with 4 μM actinomycin D, a tran-
scriptional inhibitor, blocked SDF-1–mediated HO-1 induc-
tion, and treatment with 20 μM cycloheximide, a protein 
synthesis inhibitor, showed substantial reduction of HO-1 
mRNA (Fig. 1 I). The contribution of mRNA stability in 
SDF-1–mediated HO-1 induction was then examined. After 
a maximal induction of HO-1 by SDF-1, treatment of HAECs 
with actinomycin D in the presence or absence of additional 
SDF-1 did not greatly alter HO-1 mRNA half-life ( 3 h; 
Fig. 1 H); demonstrating that HO-1 mRNA stability did 
not contribute to HO-1 induction. Collectively, these results 
show that SDF-1–mediated HO-1 induction occurs predomi-
nantly at the transcriptional level but also requires de novo 
protein synthesis.
HO-1 mediates the angiogenic response to SDF-1 in vitro
Treatment of HAECS with 100 ng/ml SDF-1 followed 
by incubation with increasing doses (0–1 μM) of zinc pro-
toporphyrin (ZnPP), an HO inhibitor, resulted in consid-
erable inhibition of SDF-1–induced endothelial tube formation 
compared with controls (Fig. 2 A). Quantitation of the 
number of branch points showed signifi  cant (P < 0.001) 
reduction in tube formation in cells treated with ZnPP 
compared with SDF-1–treated cells (Fig. 2 D). HO-1 ex-
pression was also blocked using HO-1 siRNA, and the 
eff  ect of loss of HO-1 on endothelial tube formation in 
HAECs was examined. The effi   cacy of the HO-1 siRNA 
in down-regulating HO-1 expression is shown in Fig. 2 B. 
Induction of HO-1 with hemin, a known potent HO-1 
inducer, followed by transfection with HO-1 siRNA knocked 
down HO-1 protein expression, whereas transfection with 
mock siRNA did not aff  ect HO-1. Compared with mock-
transfected cells, blockade with HO-1 siRNA resulted 
in signifi  cant  (P  < 0.001) inhibition of SDF-1–induced 
tube formation (Fig. 2 C), quantitation of which is shown 
in Fig. 2 E.
In vitro angiogenesis assays performed on MAECs iso-
lated from HO-1+/+ and HO-1−/− mice also showed that 
HO-1 defi  ciency was associated with a loss of SDF-1–mediated 
endothelial tube formation (Fig. 2, F and G). The endothelial 
phenotype of the primary MAECs was confi  rmed by uptake 
of 1,1′-dioctadecyl 3,3,3′,3′- tetramethylindocarbocyanine 
perchlorate (DiI-Ac-LDL) in both HO-1+/+ and HO-1−/− 
MAECs (Fig. 2 F, inset). Flow cytometric analysis for levels 
of the SDF-1 receptor CXCR4 showed similar levels in both 
HO-1+/+ and HO-1−/− MAECs (52 and 53%, respectively; 
Fig. 2 H). Western blot analysis of cell lysates from HO-1+/+ 
MAECs showed substantial inducibility with 100 ng/ml SDF-1 
and hemin, whereas HO-1 was not detectable in MAECs 
from HO-1−/− mice (Fig. 2 I). These results demonstrate that 608  HO-1 MEDIATES THE EFFECTS OF SDF-1 | Deshane et al.
Figure 2.  HO-1 mediates SDF-1–induced angiogenesis in vitro 
in HAECs and MAECs. (A) Representative photomicrographs showing 
inhibition of endothelial tube formation of HAECs using growth factor–
  reduced Matrigel. HAECs were treated with 100 ng/ml SDF-1 for 6 h, cells 
were detached and plated in the presence of ZnPP at the indicated con-
centrations, and tube formation was assessed at 18 h. Bars, 100 μm. 
(B) Western blot of HAEC lysates (10 μg of total protein per lane) showing 
reduction of HO-1 expression after transfection with HO-1 siRNA for 24 h. 
HAECs were treated with 5 μM hemin and transfected with the indicated 
concentrations of HO-1 or mock siRNA. The blot was stripped and rep-
robed with actin as a loading control and for specifi  city of HO-1 siRNA. 
(C) Representative photomicrographs showing inhibition of tube forma-
tion in HAECs after transfection with 200 nM HO-1 siRNA. Bars, 100 μm. 
(D and E) Quantitation of the number of endothelial tube junctions in 
HAECs treated with SDF-1 and the indicated concentrations of ZnPP (D) or 
transfected with 200 nM HO-1 siRNA or mock siRNA (E), as described in 
Materials and methods. For quantitation, images were captured from 
15 random fi  elds (n = 3 per group). Results are expressed as mean ± SEM. 
*, P < 0.001 versus SDF-1 alone. (F) Representative photomicrographs show-
ing inhibition of endothelial tube formation in MAECs isolated from 
HO-1−/− compared with HO-1+/+ mice. MAECs were isolated from HO-1+/+ 
or HO-1−/− mice as described in Materials and methods. Cells were treated 
with vehicle (PBS) or 100 ng/ml SDF-1 for 6 h and plated on Matrigel. Tube 
growth was assessed at 18 h. Insets show metabolic uptake of DiI-Ac-LDL 
(red fl  uorescence) in MAECs. Bars, 100 μm. (G) Quantitation of endothelial 
tube branch points in MAECs isolated from HO-1+/+ or HO-1−/− mice 
treated with SDF-1. No junctions were observed in vehicle-treated MAECs. 
Results are expressed as mean ± SEM. *, P < 0.001 (n = 3 per group). 
(H) FACS analysis showing comparable levels of cell surface CXCR-4 expres-
sion in MAECs isolated from HO-1+/+ and HO-1−/− mice. (I) Western blot 
of protein lysates (10 μg of total protein per lane) from HO-1+/+ and 
HO-1−/− MAECs treated with vehicle (PBS), 100 ng/ml SDF-1, or 5 μM hemin. 
Blots were probed for HO-1 and actin. Results are representative of at 
least three to four MAEC isolations from HO-1+/+ and HO-1−/− mice.JEM VOL. 204, March 19, 2007  609
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HO-1 is required for the eff  ects of SDF-1 on endothelial 
tube formation in vitro.
Effects of SDF-1 on angiogenesis in HO-1+/+ and HO-1−/− 
aortic rings ex vivo
A ring angiogenesis assay on Matrigel was performed to assess 
the ability for capillary tube sprouting from aortic segments iso-
lated from HO-1+/+ and HO-1−/− mice. Considerable diff  er-
ences in angiogenic sprouting were observed in segments isolated 
from HO-1+/+ compared with HO-1−/− mice at 5 d after stim-
ulation with 100 ng/ml SDF-1, whereas the vehicle-treated ring 
segments showed no sprouting (Fig. 3 A). The capillary sprouts 
induced by SDF-1 on aortic ring segments are of an endothelial 
phenotype, as confi  rmed by metabolic uptake of DiI-Ac-LDL 
(Fig. 3 B). These results demonstrate an important role for 
HO-1 in SDF-1–mediated angiogenesis in aortic rings ex vivo.
Figure 3.  SDF-1 induces capillary-like sprouting in aortic rings 
from HO-1+/+ but not HO-1−/− mice, and CO restores SDF-1–
  mediated angiogenesis in aortic segments from HO-1−/− mice. 
(A) Representative photomicrographs of aortic segments from HO-1+/+ 
or HO-1−/− mice grown on Matrigel and stimulated with 100 ng/ml SDF-1 
or vehicle (PBS; n = 12 per group). Capillary sprouting was assessed at 
5 d after stimulation. (B) Image showing metabolic uptake of DiI-Ac-LDL 
in capillary-like structures (red fl  uorescence) from a HO-1+/+ aortic segment 
cultured on Matrigel and stimulated with 100 ng/ml SDF-1. (C) Repre-
sentative photomicrographs of aortic ring segments from HO-1−/− mice 
cultured on Matrigel and treated with DMSO (vehicle for CORM-2), 
50 μM CORM-2, 100 ng/ml SDF-1, or 50 μM CORM-2 + 100 ng/ml SDF-1. 
(D–F) Dose–response with the indicated concentrations of CORM-2 (D), 
ICORM (E), or bilirubin (F) in the presence of 100 ng/ml SDF-1 for 5 d 
(n = 4–8 per group). Bars, 100 μm.610  HO-1 MEDIATES THE EFFECTS OF SDF-1 | Deshane et al.
CO, a byproduct of the HO enzymatic reaction, modulates 
SDF-1–mediated angiogenesis
The benefi  cial response elicited by HO-1 has been attributed 
to one or more of the byproducts of its enzymatic reaction. 
Because CO has been implicated in the angiogenic response 
associated with induction of HO-1 expression (19, 20), we 
investigated whether CO could restore the SDF-1–induced 
angiogenic eff  ects in the absence of HO-1. An increase 
in angiogenic sprouting was observed in aortic rings from 
HO-1−/− mice treated with SDF-1 in the presence of 50 μM 
of CO-releasing molecule (CORM) 2 (tricarbonyldichlororu-
thenium dimer; Fig. 3 C) (32). The eff  ect of CORM-2 was 
dose dependent, with the initial sprouting appearing at con-
centrations as low as 0.1 μM (Fig. 3 D). CORM-2 alone at 
50 μM was able to induce modest sprouting in the absence 
of SDF-1 (Fig. 3 C). The inactive compound, ICORM, 
did not induce angiogenic sprouting (Fig. 3 E). We also ex-
amined whether bilirubin could stimulate SDF-1–mediated 
  angiogenesis in HO-1−/− aortic segments. As shown in Fig. 3 F, 
bilirubin at 1, 10, and 100 μM was unable to restore the eff  ects 
of SDF-1 in the absence of HO-1, indicating that CO, not 
bilirubin, is the major HO-1 reaction product that mediates 
the proangiogenic eff  ects of SDF-1.
HO-1 plays a role in SDF-1–mediated endothelial 
cell migration
Migration and homing of endothelial cells and EPCs to the 
site of injury, an important early process in angiogenesis, 
is a response that is facilitated by SDF-1 (2–5). To investi-
gate whether HO-1 is essential for SDF-1–induced endo-
thelial cell and EPC migration, transwell fi  lters were used 
to assay for the number of HAECs migrating in response to 
100 ng/ml SDF-1 in the presence or absence of 1 μM of 
the HO inhibitor ZnPP (see Supplemental materials and 
methods). A substantial inhibition in SDF-1–mediated mi-
gration of HAECs was observed in the presence of ZnPP 
(Fig. 4 A, top). Migration of MAECs isolated from HO-1+/+ 
or HO-1−/− mice in response to SDF-1 also corroborated 
Figure 4.  HO-1 mediates SDF-1–induced migration in endothe-
lial cells and EPCs. (A) Representative photomicrographs showing 
inhibition of SDF-1–induced migration by 1 μM ZnPP in HAECs using 
transwell fi  lters (pore diameter = 5 μm). (bottom) Reduced numbers of 
migrating MAECs isolated from HO-1−/− compared with HO-1+/+ mice 
in response to SDF-1. (B) Histogram showing quantitation of migrating 
cells in HO-1+/+ compared with HO-1−/− MAECs in response to vehicle 
(PBS) or 100 ng/ml SDF-1. Results are expressed as mean ± SEM. 
*, P < 0.001 versus vehicle-treated groups; #, P < 0.001 versus SDF-1–
treated HO-1+/+ cells (n = 3 per group). (C) FACS analysis showing cell 
surface expression of CXCR-4 and CD31 in circulating EPCs isolated 
from HO-1−/− mice. Similar numbers were observed in HO-1+/+ EPCs 
(not depicted). The inset shows a Western blot for HO-1 and actin per-
formed on EPCs isolated from HO-1+/+ mice and treated with vehicle 
(PBS) or 100 ng/ml SDF-1. (D) Representative images of crystal violet–
stained EPCs on transwell fi  lters showing increased SDF-1–induced 
migration of HO-1+/+ compared with HO-1−/− cells. Insets show 
EPCs that are able to take up DiI-Ac-LDL, a marker for endothelial 
cells. (E) Quantitation of the number of migrating EPCs in response to 
100 ng/ml SDF-1 in HO-1+/+ and HO-1−/− EPCs. Results are expressed 
as mean ± SEM. *, P < 0.001 versus SDF-1–treated HO-1+/+ EPCs. 
Bars, 100 μm.JEM VOL. 204, March 19, 2007  611
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the signifi  cance of HO-1 in endothelial migration. Signifi  -
cant inhibition of SDF-1–induced migration was observed 
in MAECs from HO-1−/− mice when compared with 
HO-1+/+ MAECs (Fig. 4 A, bottom; and Fig. 4B). Because 
circulating progenitor cells are key mediators in initiating 
angiogenesis, we examined the migratory potential of EPCs 
isolated from HO-1+/+ or HO-1−/− mice. Flow cytometric 
analysis indicated that 89.3% of cells expressed the SDF-1 
receptor CXCR4, were positive for the endothelial marker 
CD31 (Fig. 4 C; see Supplemental materials and methods), 
and were able to take up DiI-Ac-LDL (Fig. 4 D, insets). 
HO-1+/+ EPCs also showed induction of HO-1 protein 
after exposure to 100 ng/ml SDF-1 (Fig. 4 C, inset), whereas 
no induction was observed in HO-1−/− EPCs (not depicted). 
In response to SDF-1, signifi  cantly higher numbers of HO-1+/+ 
EPCs migrated compared with HO-1−/− EPCs (Fig. 4, D 
and E). These results indicate that HO-1 is important for 
the SDF-1–induced migratory response of endothelial cells 
and EPCs.
SDF-1–mediated HO-1 induction is VEGF independent
VEGF has been shown to modulate HO-1 levels (21, 29), 
and SDF-1 has also been shown to induce VEGF levels 
(33, 34). Therefore, we explored the involvement of VEGF 
in the proangiogeneic eff  ects of SDF-1 and HO-1 gene ex-
pression. Pretreatment of HAECs with h-VEGF antibodies, 
at concentrations to achieve 50 or 100% neutralization, did 
not inhibit SDF-1–mediated HO-1 mRNA induction (Fig. 
S1 A, available at http://www.jem.org/cgi/content/full/jem
.20061609/DC1). In addition, SDF-1–induced capillary 
sprouting of mouse aortic ring segments and endothelial 
tube formation in HAECs were not aff  ected by neutralizing 
VEGF, which on the other hand blocked VEGF-induced 
tube formation (Fig. S1, B–D). Antibodies to SDF-1 and 
AMD3100 inhibited capillary sprouting and endothelial tube 
formation (Fig. S1, B and C). Moreover, VEGF levels in 
media after stimulation of HAECs by SDF-1 or hemin were 
not substantially increased (not depicted).
To examine if there was synergy between SDF-1 and 
VEGF, we also investigated the eff  ects of increasing levels of 
VEGF in the presence of a lower concentration (10 ng/ml) 
of SDF-1 on endothelial tube formation in HAECs (Fig. 
S1 D). An increase in tube formation was observed with the 
combination of SDF-1 + VEGF, but this was not signifi  -
cantly diff  erent than that observed with SDF-1 alone and was 
not inhibited by the VEGF antibody (Fig. S1 D). Collec-
tively, these results suggest a VEGF-independent mechanism 
for the HO-1 induction by SDF-1.
PKC-𝗇 regulates SDF-1–mediated HO-1 induction
Recent experiments have suggested a direct involvement for 
PKC-ζ, an atypical PKC isoform, in signaling events and 
  migration mediated by the SDF-1/CXCR-4 axis in human 
CD34+ hematopoietic progenitors (35). We therefore inves-
tigated the potential role of PKC-ζ in regulating SDF-1–
  mediated HO-1 expression and angiogenic eff  ects in endothelial 
Figure 5.  PKC-𝗇 regulates SDF-1–mediated HO-1 induction and 
its proangiogenic effects. (A) Inhibition of SDF-1–mediated HO-1 
mRNA induction in HAECs by a myristoylated peptide inhibitor of PKC-ζ 
compared with Gö6976, a PKC α/β inhibitor, at the indicated concentra-
tions. HAECs were incubated with the PKC inhibitors for 15 min and stim-
ulated with 100 ng/ml SDF-1 for 4 h. (B) Quantitation of endothelial tube 
junctions in HAECs after treatment with the indicated concentrations of 
the PKC inhibitors in response to SDF-1. Results are expressed as mean ± 
SEM. #, P < 0.001; and *, P < 0.05 versus SDF-1. (C) Representative photo-
micrographs of aortic ring segments cultured on Matrigel from HO-1+/+ 
mice showing inhibition of capillary sprouting when pretreated with 1 or 
10 μM PKC-ζ inhibitor peptide followed by stimulation with SDF-1, com-
pared with treatment with 10 μM Gö6976. Bars, 100 μm. (D) PKC-ζ–
dependent and VEGF-independent activation of a human HO-1 promoter 
by SDF-1. HAECs were transfected with a 9.4-kb human HO-1 promoter 
construct (pHOGL3/9.4), as described in Supplemental materials and 
methods. Cells were exposed to vehicle, control, 10 μM PKC-ζ inhibitor 
peptide, 10 μM Gö6976, 50 ng/ml VEGF, 5 μM SU 5416, 0.1 μg/ml of 
neutralizing VEGF antibody (VEGF ab), and 25 nM AMD 3100 for 15 min, 
followed by treatment with 100 ng/ml SDF-1 for 16 h, and luciferase as-
says were performed. Results are expressed as mean ± SEM and are de-
rived from fi  ve independent experiments (n = 3 per group). #, P < 0.001 
versus SDF-1; *, P < 0.001 versus vehicle.612  HO-1 MEDIATES THE EFFECTS OF SDF-1 | Deshane et al.
cells. Exposure of HAECS to 100 ng/ml SDF-1 resulted in a 
1.3-, 2.4-, and 3.8-fold activation of PKC-ζ at 5, 10, and 
15 min, respectively (unpublished data). Blockade of PKC-ζ 
using a myristoylated peptide inhibitor (35), but not PKC-α/β 
(using Gö6976), eliminated induction of HO-1 by SDF-1 
(Fig. 5 A) and also inhibited endothelial tube formation and 
capillary sprouting (Fig. 5, B and C). Inhibition of PKC-ζ 
also blocked SDF-1–driven activity of a 9.4-kb human HO-1 
promoter (Fig. 5 D). The specifi  city of HO-1 promoter 
  activation by SDF-1 was also confi  rmed using AMD3100, 
VEGF antibody, and a VEGF receptor–2 antagonist (SU5416; 
Fig. 5 D). These results demonstrate that HO-1 induction 
by SDF-1 and consequent proangiogenic eff  ects are PKC-ζ 
dependent and VEGF independent.
Requirement of HO-1 for SDF-1–mediated angiogenesis 
in vivo
Matrigel was implanted subcutaneously into fl  anks of HO-1+/+ 
and HO-1−/− mice in the presence or absence of 100 ng/ml 
SDF-1. Matrigel plugs harvested 7 d after implantation re-
vealed a signifi  cant (P < 0.001) decrease in blood vessel den-
sity and mean area occupied by RBCs in HO-1−/− compared 
with HO-1+/+ mice (Fig. 6, A and B). To verify that the area 
occupied by RBCs was indeed blood vessels, CD31 staining 
and ultrastructural analysis was performed on Matrigel plugs. 
Cells lining the walls of the new capillaries in the Matrigel 
plugs were positive for CD31 (Fig. 6 A, bottom left, inset). 
Transmission electron microscopy showed spindle-shaped 
cells with free-fl  owing nuclei containing both eu- and hetero-
chromatin, focally prominent rough endoplasmic reticulum, 
and mitochondria in the cytoplasm with rare microvilli and 
junctional complexes (Fig. 6 C). These features are consistent 
with primitive endothelial cells proliferating within the extra-
cellular matrix of the Matrigel plugs.
Impaired wound healing in HO-1–defi  cient mice
Serum levels of SDF-1 were not signifi  cantly diff  erent in 
HO-1−/− compared with HO-1+/+ mice (890 ± 105 vs. 924 ± 
112 pg/ml; P = NS; n = 4 per group; see Supplemental 
materials and methods). The absence of HO-1 was associated 
with impaired wound healing and a diminished angiogenic 
response after full-thickness excisional skin wound injury. 
The percentage of reepithelialized surface after wound injury 
was signifi  cantly lower in HO-1−/− compared with HO-1+/+ 
mice at days 1–3 (Fig. 7 A), and the number of CD31-positive 
vessels was signifi  cantly decreased in wounds in HO-1−/− 
compared with HO-1+/+ mice at days 3 and 17 (Fig. 7, 
B and C). In addition, topical application of SDF-1 to the 
wound surface, delivered using Matrigel, increased neovascu-
larization in HO-1+/+ mice but was ineff  ective in HO-1−/− 
mice (Fig. 7, D and E).
Presence of HO-1 in EPCs is necessary for retinal 
vascular repair
Adoptive transfer was used to directly examine the contribu-
tion of the EPCs from HO-1−/− versus wild-type mice in an 
Figure 6.  SDF-1–induced angiogenesis in Matrigel plugs in vivo 
in HO-1+/+ and HO-1−/− mice. (A) Representative photomicrographs 
of Masson trichrome–stained paraffi  n-embedded sections of implanted 
Matrigel plugs treated with vehicle (PBS) or 100 ng/ml SDF-1 from 
HO-1+/+ and HO-1−/− mice (n = 4–5 per group). Insets shows a higher 
magnifi  cation of two capillaries with CD31 (red) and DAPI (blue) staining 
in the Matrigel. Bars, 100 μm. (B) Histogram showing average RBC area 
per 1.3 × 108 μM2. Quantitation was done using Image-Pro software on 
an average of 20 random fi  elds by two independent investigators in a 
blinded fashion, as described in Supplemental materials and methods. 
Results are expressed as mean ± SEM. *, P < 0.001 versus vehicle-treated 
HO-1+/+ mice; #, P < 0.001 versus SDF-1–treated HO-1+/+ mice. 
(C) Transmission electron microscopy of Matrigel plugs showing ultra-
structural features consistent with endothelial cells in the Matrigel (asterisk). 
Spindle-shaped cells with free-fl  owing nuclei, focally prominent rough 
endoplasmic reticulum and mitochondria with rare microvilli (inset, 
  arrow), and junctional complexes. Bar, 4.2 μm.JEM VOL. 204, March 19, 2007  613
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in vivo model of retinal ischemia–induced vascular repair 
that requires endogenous SDF-1 (15). SDF-1 levels were in-
creased in the injured eyes compared with the contralateral, 
uninjured eyes of wild-type mice that were used as recipients 
of EPCs from HO-1+/+ or HO-1−/− mice (Fig. 8 A; see 
Supplemental materials and methods). We also measured 
SDF-1 levels in injured and uninjured (contralateral) eyes 
from HO-1+/+ or HO-1−/− mice and observed a signifi  cant 
increase in SDF-1 levels in injured eyes, but no  signifi  cant 
diff  erences were observed between the HO-1+/+ versus the 
HO-1−/− mice (Fig. 8 B).
EPCs from HO-1+/+ or HO-1−/− mice were adminis-
tered directly into the vitreous humor of wild-type mice that 
had undergone ischemia/reperfusion injury to the retina that 
resulted in a damaged retinal endothelium with vasooblitera-
tion and generation of acellular capillaries. The fl  uorescently 
labeled HO-1+/+ EPCs homed to acellular regions, adhered, 
assimilated into injured regions, and resulted in reendotheli-
alization of nonperfused capillaries within the retina (Fig. 
8 C, top; and Video 1, available at http://www.jem.org/cgi/
content/full/jem.20061609/DC1). In contrast, the HO-1−/− 
EPCs were impaired in their ability to migrate into the areas 
of ischemia and repair the acellular capillaries (Fig. 8 D, top; 
and Video 2). Contralateral uninjured retinas showed no 
  incorporation of labeled EPCs (Fig. 8, C and D, bottom). 
These in vivo results demonstrate the robust reparative po-
tential of EPCs from HO-1+/+ mice in comparison with 
HO-1−/− mice. Collectively, the results implicate HO-1 as 
an important mechanistic link for the angiogenic eff  ects of 
SDF-1 in vivo.
Figure 7.  Skin reepithelialization after injury in HO-1+/+ and 
HO-1−/− mice. (A) Histogram showing the percentage of nonreepithelialized 
surface at the site of the wound in HO-1+/+ and HO-1−/− mice. Results are 
expressed as mean ± SEM (n = 4–5 per group). The wound healing model 
was performed as described in Materials and methods, and measurements 
were taken at days 0–9 after injury. *, P < 0.05; **, P < 0.001; #, P < 0.01. 
(B) Histogram showing CD31-positive–stained vessels (arbitrary units) from 
HO-1+/+ and HO-1−/− skin sections at days 3 and 17. Results are expressed 
as mean ± SEM (n = 4–5 per group). *, P < 0.05. (C) Representative photo-
micrographs of CD31-positive cells in the healing skin sections from 
HO-1+/+ and HO-1−/− mice at days 3 and 17 after injury. Bars, 100 μm. 
(D) Histogram showing CD31-positive–stained area (expressed as the per-
centage of arbitrary units) from HO-1+/+ and HO-1−/− skin sections after 
topical application of Matrigel-containing vehicle (PBS) or 100 ng/ml SDF-1 
(25 μl/wound). The wound healing model was performed as described in 
Materials and methods, and skin sections were harvested at 5 d after 
injury. Results are expressed as mean ± SEM (n = 4–5 per group). *, P < 
0.001 versus vehicle-treated HO-1+/+ mice; #, P < 0.01 versus SDF-treated 
HO-1+/+ mice. (E) Representative photomicrographs of CD31-positive cells 
in healing skin sections for the data shown in D. Bars, 20 μm.614  HO-1 MEDIATES THE EFFECTS OF SDF-1 | Deshane et al.
SDF-1–mediated VASP phosphorylation is HO-1 dependent
To begin to elucidate the downstream eff  ectors of HO-1 
and CO, we examined the eff  ects of SDF-1 on VASP, a 
  cytoskeletal-associated protein localized at cell–cell contacts 
and microfi  laments that has been implicated in EPC migration 
(36). Treatment of MAECs with 100 ng/ml SDF-1 for 2 h 
resulted in VASP phosphorylation at serine 239 in HO-1+/+ 
cells but not in endothelial cells from HO-1−/− mice (Fig. 
9 A). Importantly, treatment with 10 μM CORM-2 for 
30 min was able to phosphorylate VASP in both HO-1+/+ 
and HO-1−/− cells (Fig. 9 A).
We then explored the eff  ects of CORM-2 on VASP 
in equine EPCs (see Supplemental materials and methods) 
and observed a considerable redistribution of VASP to the 
  fi  lopodia after treatment with 10 μM CORM-2 for 15 min 
(Fig. 9 B). These results suggest a potentially novel mecha-
nism by which CO, a product of HO-1 activation, modu-
lates SDF-1–induced endothelial migration, a primary event 
in angiogenesis.
D  I  S  C  U  S  S  I  O  N 
The SDF-1–CXCR4 axis is a pivotal regulator of traffi   cking 
and homing of various cell types, including EPCs (5, 35–37). 
There has also been considerable evidence to support the role 
of circulating EPCs in adult neovascularization (38, 39), 
though the mechanism of recruitment of these cells and their 
angiogenic potential is not completely understood. In this 
Figure 8.  Adoptive transfer (intravitreal) of HO-1+/+ or HO-1−/− 
EPCs after retinal ischemia. (A) SDF-1 levels in the injured left eye (LE) 
and the contralateral, uninjured right eye (RE) of the wild-type recipient 
at the indicated time points measured using ELISA, as described in Sup-
plemental materials and methods. Results are expressed as mean ± SEM. 
(B) SDF-1 levels in the injured (LE) and control (RE) eyes of age-matched 
HO-1+/+ (n = 4) and HO-1−/− (n = 3) mice at 6 h after injury. Results are 
expressed as mean ± SEM. #, P < 0.001, injured versus control. (C, top) 
Representative confocal images of retinal fl  at mounts showing PKH67-
labeled EPCs (green) from HO-1+/+ mice in the vasculature (labeled with 
rhodamine-conjugated agglutinin; red), compared with eyes injected with 
HO-1−/− EPCS (D, top). Contralateral, noninjected eyes are shown as con-
trols (C and D, bottom). Arrows indicate colocalization in the merged im-
ages. Bar, 50 μm.
Figure 9.  Effects of SDF-1– and HO-1–derived CO on phosphory-
lation and redistribution of VASP. (A) Western blot analysis of HO-1+/+ 
or HO-1−/− MAECs treated with either 100 ng/ml SDF-1 for 2 h or CORM-2 
for 30 min at the indicated concentrations and probed for levels of phospho-
VASP (ser 239 [p-VASP]), total VASP, HO-1, and actin, as described in 
Materials and methods. (B) Representative photomicrographs of equine 
EPCs after 1 wk of culture on fi  bronectin-coated coverslips treated with 
10 μM CORM-2 for 15 min before fi  xation and immunofl  uorescence 
microscopy. (left) Untreated cells with diffuse staining for VASP (green) 
in the cytoplasm. (right) CORM-2–induced redistribution of VASP to 
fi  lopodia (arrow). DAPI was used to stain nuclei. Bars, 5 μm. JEM VOL. 204, March 19, 2007  615
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study, we provide in vitro, ex vivo, and in vivo data that 
demonstrate a critical role for HO-1 in SDF-1–mediated 
  angiogenesis through a PKC-ζ–dependent mechanism. Our 
results show that SDF-1 is an inducer of the cytoprotective 
enzyme HO-1 in HAECs and MAECs and EPCs. We also 
propose a role for HO-1 in SDF-1–mediated endothelial 
tube formation from in vitro studies using HO inhibitors, as 
well as HO-1 siRNA in HAECs. Substantial inhibition of 
SDF-1–induced tube formation resulted from chemical inhi-
bition of HO with ZnPP and RNA interference of HO-1. 
The functional signifi   cance of HO-1 in SDF-1–mediated 
angiogenesis was further demonstrated in MAECs derived 
from HO-1+/+ and HO-1−/− mice, wherein SDF-1 was un-
able to induce tube formation in HO-1−/− compared with 
HO-1+/+ MAECs. The present experiments also support a 
considerable contribution of HO-1 and VASP as one poten-
tial downstream eff  ector of SDF-1–mediated migration of 
endothelial cells and EPCs, an early event in angiogenesis 
(3, 40). Furthermore, HO-1 was required for the eff  ects of 
SDF-1 in multiple in vivo models. The combined data show 
that HO-1 was required for SDF-1–induced angiogenesis in 
the adult mouse.
Previous studies have implicated a role for HO-1 in 
angiogenesis (16–21). Pharmacologic or genetic maneuvers 
that increase HO-1 expression enhance proliferation and 
tube formation in human microvascular endothelial cells 
in vitro (18–20), whereas antisense inhibition of HO-1 de-
creases tube formation, a phenomenon independent of HO-2 
(18–20). The present studies linking the proangiogenic 
eff  ects of SDF-1 to HO-1 resemble the proposed involve-
ment of HO-1 in VEGF-induced angiogenesis. Similar to 
our results with SDF-1, VEGF also induces HO- 1  expression 
and infl  uences angiogenesis (20, 21, 41). In addition, SDF-1 
enhances VEGF expression (33, 34). However, the results 
of our study provide direct evidence to demonstrate that the 
induction of HO-1 and the proangiogenic eff  ects of SDF-1 
are VEGF independent. First, blockade of VEGF did not af-
fect SDF-1–stimulated HO-1 mRNA and promoter activity 
(Fig. S1 and Fig. 5 D). Second, VEGF neutralization did not 
reverse the proangiogenic eff  ects of SDF-1 both in vitro and 
ex vivo (Fig. S1, B–D). Third, we were unable to detect an 
increase in VEGF after SDF-1 or hemin stimulation in aortic 
endothelial cells. In addition, VEGF levels from control and 
injured eyes of HO-1+/+ and HO-1−/− mice did not in-
crease and were not notably diff  erent at 6 h after injury (not 
depicted), a time point when signifi  cant increases in SDF-1 
levels were observed in injured eyes (Fig. 8 B). VEGF lev-
els in the skin wound healing model from HO-1+/+ and 
HO-1−/− mice were also not substantially diff  erent at 7 d 
  after injury (unpublished data), consistent with our fi  ndings in 
the eye injury model. Fourth, the time course of HO-1 in-
duction by SDF-1 (as early as 2 h; Fig. 1 A) is not consistent 
with the kinetics of either SDF-1–induced VEGF activation 
(6 h) ( 33) or VEGF-mediated HO-1 induction (24–48 h) 
(21, 29). Furthermore, previous experiments using intra-
vitreal injection of blocking antibodies to SDF-1 prevented 
retinal neovascularization, even in the presence of exogenous 
VEGF (15).
Recent studies performed in vitro have shown that 
proangiogenic properties of HO-1 are attributable to CO 
(19, 20, 41). Our results demonstrate that CO can substitute 
for HO-1 in SDF-1–mediated angiogenesis. The addition of 
CORM-2 was able to restore the responsiveness of HO-1−/− 
aortic rings to SDF-1, providing direct evidence for CO-
  dependent modulation of the eff  ects of SDF-1. Although 
CO is known as a cellular messenger with signaling functions 
similar to NO, the possibility of other downstream eff  ectors 
or alternate mechanisms for the actions of CO is not clearly 
understood. We explored one potential mechanism and show 
that CO causes redistribution and phosphorylation of the 
  cytoskeletal associated protein VASP in EPCs and MAECs 
(Fig. 9). SDF-1 was able to phosphorylate VASP at the cyclic 
guanosine monophosphate–dependent protein kinase–preferred 
site (serine 239) in HO-1+/+ but not in HO-1−/− MAECS 
(Fig. 9 A). On the other hand, CORM-2 induced VASP 
phosphorylation in both HO-1+/+ and in HO-1−/− cells, 
suggesting that HO-1–derived CO was a potential down-
stream eff  ector for this response. Whether SDF-1 is regulated 
by CO is not known. In preliminary studies, we did not 
  detect a substantial increase in SDF-1 levels after exposure 
(up to 48 h) to CORM-2 or with hemin (a potent HO-1 
  inducer) in conditioned media from HAECs. In addition, 
CORM-2 did not modulate CXCR-4 expression (unpub-
lished data).
Previous studies have indicated that inhibition of angio-
genesis can delay wound healing in excision models in mice 
(42). Proangiogenic factors such as VEGF counteract this ef-
fect by increasing tissue granulation and wound vascularity   
(42, 43). Recent studies have shown that SDF-1 infl  uences 
retention of recruited bone marrow–derived circulating cells 
near new blood vessels induced by VEGF and vice versa (44). 
SDF-1 has also been proposed to function as an entrapment 
funnel to capture homing CXCR-4+ cells (44). Our studies 
implicate HO-1 as an important intermediate in this auto-
crine loop involving SDF-1 and could explain the underlying 
mechanism for the results observed in the wound healing 
and Matrigel plug models in HO-1+/+ and HO-1−/− mice. 
A considerable decrease in the reepithelialization and number 
of CD31-positive cells was observed at the site of the wound 
in HO-1−/− compared with HO-1+/+ mice. In addition, the 
capillary density in SDF-1–containing Matrigel plugs im-
planted in HO-1−/− mice was substantially reduced com-
pared with HO-1+/+ mice. Furthermore, the results from 
our adoptive transfer experiments in retinal injury also dem-
onstrate the requirement of HO-1 for homing and integra-
tion of EPCs into acellular capillaries.
In summary, the present studies provide evidence that 
HO-1 is required for the eff  ects of SDF-1 in angiogenesis. 
A working model for our fi  ndings is shown in Fig. 10. SDF-1, 
through the CXCR-4 receptor, transcriptionally activates 
HO-1 via the atypical PKC-ζ isoform. Increased HO en-
zyme activity results in the generation of CO, which was able 616  HO-1 MEDIATES THE EFFECTS OF SDF-1 | Deshane et al.
to substitute for the absence of HO-1 and restore the pro-
angiogenic eff  ects of SDF-1. We have identifi  ed VASP, a 
  cytoskeletal-associated protein involved in migration, as a 
downstream target for SDF-1 that requires HO-1– derived 
CO for phosphorylation. Other potential mechanisms, in-
cluding the eff  ects of CO on cell cycle regulatory proteins 
such as p21, cell proliferation, and the recruitment of bone 
marrow–derived cells, could also contribute to the proangio-
genic eff  ects of HO-1 (19, 45). These fi  ndings demonstrate a 
novel role for HO-1 in SDF-1–mediated angiogenesis and in 
the regulation of primary events such as endothelial migra-
tion and neovascularization.
MATERIALS AND METHODS
Reagents. Anti–human SDF-1 antibody, anti–mouse and anti–human and 
anti–mouse VEGF antibodies, and recombinant human and mouse SDF-1α 
were obtained from R&D Systems. Recombinant human VEGF was pur-
chased from PeproTech. Anti–mouse CD31 antibody and PE-conjugated 
rat anti–mouse and mouse anti–human CXCR4 monoclonal antibodies 
were obtained from BD Biosciences. Anti–human VASP antibody was pur-
chased from Cell Signaling Technology, and anti–phospho-VASP (ser 239) 
was purchased from Upstate Cell Signaling Solutions. PE-conjugated anti–
mouse CD31 antibody was obtained from Santa Cruz Biotechnology, Inc. 
ZnPP and bilirubin were purchased from Frontier Scientifi  c, Inc. Anti–HO-1 
antibody was obtained from StressGen Biotechnologies. Gö6976 was pur-
chased from EMD Biosciences, Inc., and myristoylated PKC-ζ peptide 
  inhibitor was obtained from BIOMOL Research Laboratories, Inc. All other 
reagents were purchased from Sigma-Aldrich.
Cell culture. HAECs (Clonetics) were maintained in endothelial basal me-
dia (Clonetics) supplemented with 6 μg/ml bovine brain extract, 10 ng/ml 
human epidermal growth factor, 1 μg/ml hydrocortisone, 50 μg/ml genta-
micin, 50 μg/ml amphotericin B, and 10% FBS. Primary MAECs were 
  isolated from HO-1+/+ and HO-1−/− mice and maintained as described 
previously (46).
Animals. 8–12-wk-old HO-1−/− mice and HO-1+/+ littermates (C57BL/6 × 
FVB background) were used for all experiments. For the wound healing 
studies, HO-1−/− and HO-1+/+ littermate mice were generated from breed-
ing pairs of HO-1+/− mice transferred to Krakow from the original colony 
maintained at Birmingham. The animal protocols were approved by the In-
stitutional Animal Care and Use Committees at the University of Alabama 
at Birmingham and at the Jagiellonian University.
HO enzyme activity. HO activity was measured as previously described (47).
siRNA studies. HO-1 siRNA against the target sequence 5′ A  A  G  G  A  G  A-
U  U  G  A  G  C  G  C  A  A  C  A  A  G   3′ in the deprotected, duplexed, desalted, and pu-
rifi  ed form (Dharmacon) was used for HO-1 knockdown studies (48). Mock 
siRNA (5′ A  A  U  G  G  A  A  G  A  C  C  A  C  U  C  C  C  A  C  U  C   3′) was used as a control. 
HAECs were induced with 5 μM hemin for 4 h and then transfected with 
HO-1 siRNA and mock siRNA at concentrations ranging from 200–800 nM 
using Oligofectamine (Invitrogen). HO-1 levels were analyzed by Western 
blot at 24 h after transfection. For angiogenesis studies, cells were transfected 
with 200 nM HO-1. siRNA was compared with controls (mock siRNA) for 
the ability to form endothelial tubes in response to SDF-1.
In vitro angiogenesis assay. HAECs and MAECs were treated with 100 
ng/ml SDF-1 for 6 h in 1% serum containing media and detached with 
Versene (0.53 mM EDTA), viable cells were counted, and a single-cell sus-
pension (at a density of 2 × 105 cells/ml) prepared. 200 μl of growth factor–
reduced Matrigel (BD Biosciences) was plated in a 48-well plate and 
incubated at 37°C for 15 min. 200 μl of cell suspension was plated on the 
Matrigel, with PBS-treated cells as a control. For inhibitor studies, cells were 
incubated with or without SDF-1, detached, and plated with ZnPP at doses 
ranging from 100 nM to 1 μM. After plating on Matrigel, endothelial tube 
formation was evaluated after incubation for 18 h at 37°C, as described pre-
viously (49).
Aortic ring angiogenesis. Aortic segments were isolated from HO-1+/+ 
and HO-1−/− mice and carefully placed with the lumen of the ring opened 
up on Matrigel with 100 μl of endothelial basal media in a 96-well glass-
  bottom tissue culture plate (50). The rings were allowed to incubate at 
37°C/5% CO2 for 48 h, stimulated with or without 100 ng/ml SDF-1 or 
VEGF (1, 10, and 50 ng/ml), and assayed for capillary sprouting. To evaluate 
the eff  ects of CO and bilirubin, aortic ring segments were incubated in 
  media containing increasing doses of CORM-2 (0.1, 1, 10, and 50 μM) or 
bilirubin (1, 10, and 100 μM) for 24 h, stimulated with 100 ng/ml SDF-1, 
and assayed for tube formation after 5 d. ICORM (CORM exposed to air 
for 24 h in media) was used as a negative control.
Isolation of circulating EPCs. Circulating EPCs were isolated as de-
scribed previously (51). The endothelial phenotype of the progenitor cells 
was validated by labeling cells using 10 μg/ml DiI-Ac-LDL and CD31 stain-
ing. Equine EPCs were isolated as previously described (36).
Matrigel plug model of angiogenesis in vivo. Growth factor–reduced, 
phenol red–free Matrigel (BD Biosciences) either alone (PBS-treated) or 
supplemented with 100 ng/ml SDF-1 in a volume of 500 μl was injected 
subcutaneously into the fl  anks of HO-1+/+ or HO-1−/− mice under isofl  u-
rane anesthesia (n = 4–5 per group). After 7 d, the animals were killed, and 
Matrigel plugs were harvested and fi  xed in 10% neutral-buff  ered formalin 
solution. Tissues were processed and analyzed as described in Supplemental 
materials and methods.
Wound healing model of angiogenesis. HO-1+/+ and HO-1−/− mice 
were anesthetized with isofl  urane and shaved, and the skin was disinfected 
with 70% ethanol. Two full-thickness excisional wounds, both 3 mm in 
  diameter, were generated on either side of the dorsal midline of each mouse 
with a disposable biopsy punch tool (Stiefel). The wounds were separated 
well by >1.5 cm of skin. Each wound was photographed every day using a 
Figure 10.  Proposed model for HO-1–dependent mechanism for 
the proangiogenic effects of SDF-1. SDF-1, through the CXCR-4 
  receptor, transcriptionally activates HO-1 via the atypical PKC-ζ isoform. 
CO, a byproduct of SDF-1–induced–increased HO enzyme activity, phos-
phorylates VASP, a cytoskeletal-associated protein involved in migration, 
a critical event in angiogenesis. Other potential mechanisms for the 
downstream mediators of HO-1/CO may also contribute to the proangio-
genic effects.JEM VOL. 204, March 19, 2007  617
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camera (EOS350D; Canon) with an objective (EF-S 60mm f/2.8 Macro 
USM; Canon). Wound surfaces were measured using the ImageJ program 
(National Institutes of Health [NIH]) and expressed as a percentage of the 
wound area at day 0. In another set of animals, the wound surface was cov-
ered with Matrigel with or without 100 ng/ml SDF-1 (25 μl/wound) im-
mediately after injury. Animals were killed at days 3, 5, and 17 after injury, 
and complete wounds, including 2.5 mm of adjacent normal skin, were ex-
cised. Cryosections were stained with anti-CD31, as described in Supple-
mental materials and methods.
In vivo retinal ischemia/reperfusion studies. Retinal ischemia was 
  induced in C57BL/6J mice (The Jackson Laboratory) at 7–10 wk of age by 
elevation of the intraocular pressure for 2 h, as described in Supplemental 
materials and methods.
Statistical analysis. Results are expressed as mean ± SEM and are 
derived from at least three independent experiments. The Student’s t test 
and analysis of variance with the Student-Newman-Keuls posttest were used 
for comparisons.
Online supplemental material. Supplemental materials and methods 
contains information about the Northern and Western blot analyses, fl  ow 
cytometry, migration assay, plasmid construct and transfection, Matrigel plug 
model, immunohistochemistry and immunocytochemistry, SDF-1 and 
VEGF ELISA, retinal ischemia/reperfusion studies, and references for the 
section. Fig. S1 shows VEGF-independent eff  ects of SDF-1–mediated HO-1 
induction. Video 1 shows homing of fl  uorescently labeled HO-1+/+ EPCs 
to retinal capillaries. Video 2 shows impaired homing of fl  uorescently labeled 
HO-1−/− EPCs to retinal capillaries. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20061609/DC1.
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